StockData
Guardant Health, Inc. logo

Guardant Health, Inc. (GH) stock

GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$145.14+1.86 (+1.30%)

Close on Nov 18, 2026Market cap $19.48BP/E –Yield –

Earnings

Guardant Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 18, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$361.00M
+36.1% on a year earlier
Non-GAAP net loss per share, Q3 FY2026
-$0.29
-$0.39 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Guardant Health's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 18, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$361.00M+36.1%-$0.93-$0.29Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026after the close$335.00M+44.3%-$0.90-$0.42Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$301.70M+48.3%-$0.85-$0.45Release
Q4 FY2025ended Dec 31, 2025Feb 19, 2026after the close$281.30M+39.4%-$1.00-$0.50Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025after the close$265.20M+38.5%-$0.74-$0.39Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025after the close$232.10M+31.0%-$0.80-$0.44Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025after the close$203.50M+20.8%-$0.77-$0.49Release
Q4 FY2024ended Dec 31, 2024Feb 20, 2025after the close$201.80M+30.1%-$0.90-$0.62Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$191.50M+33.9%-$0.88-$0.45Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close$177.20M+29.2%-$0.84-$0.48Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$168.50M+30.9%-$0.94-$0.46Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Guardant Health's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$1.36B – $1.37B$1.25B – $1.28BRaisedNov 5, 2026
revenueFY2026$1.34B – $1.36B$1.30B – $1.32BRaisedJul 30, 2026
revenue growthFY2026+36% – +38%+32% – +34%RaisedJul 30, 2026
non-GAAP gross marginnon-GAAPFY202665%64% – 65%RaisedNov 5, 2026
non-GAAP gross marginnon-GAAPFY202664% – 65%64% – 65%ReaffirmedJul 30, 2026
free cash flow burnFY2026$195.00M – $205.00M$185.00M – $195.00MRaisedJul 30, 2026
full-year free cash flow burnnon-GAAPFY2026$205.00M – $220.00M$185.00M – $195.00MRaisedNov 5, 2026
Oncology revenue growthFY2026+30%+28% – +29%RaisedJul 30, 2026
Oncology volume growthFY2026+50%–RaisedJul 30, 2026
Shield volumeFY2026270,000 – 285,000230,000 – 245,000RaisedJul 30, 2026
total non-GAAP operating expensesnon-GAAPFY2026$1.11B – $1.13B$1.03B – $1.05BRaisedNov 5, 2026
total non-GAAP operating expensesnon-GAAPFY2026$1.08B – $1.10B$1.05B – $1.07BRaisedJul 30, 2026

Guidance vs results

The last range Guardant Health gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$965.00M – $970.00M$982.10MΣ4QAbove range
FY2025Revenue growth+31%+32.9%Σ4QAbove range

Guidance history

Every forecast Guardant Health put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026full-year free cash flow burnFY2026$205.00M – $220.00MRaised
Nov 5, 2026non-GAAP gross marginFY202665%Raised
Nov 5, 2026total non-GAAP operating expensesFY2026$1.11B – $1.13BRaised
Nov 5, 2026revenueFY2026$1.36B – $1.37BRaised
Jul 30, 2026free cash flow burnFY2026$195.00M – $205.00MRaised
Jul 30, 2026non-GAAP gross marginFY202664% – 65%Reaffirmed
Jul 30, 2026Shield volumeFY2026270,000 – 285,000Raised
Jul 30, 2026Oncology revenue growthFY2026+30%Raised
Jul 30, 2026Oncology volume growthFY2026+50%Raised
Jul 30, 2026total non-GAAP operating expensesFY2026$1.08B – $1.10BRaised
Jul 30, 2026revenue growthFY2026+36% – +38%Raised
Jul 30, 2026revenueFY2026$1.34B – $1.36BRaised
Jul 30, 2026Screening revenueFY2026$218.00M – $230.00MLowered
May 7, 2026free cash flow burnFY2026$185.00M – $195.00MNew
May 7, 2026non-GAAP gross marginFY202664% – 65%New
May 7, 2026Shield volumeFY2026230,000 – 245,000New
May 7, 2026Oncology revenue growthFY2026+28% – +29%New
May 7, 2026total non-GAAP operating expensesFY2026$1.05B – $1.07BNew
May 7, 2026growthFY2026+32% – +34%New
May 7, 2026full year 2026 revenueFY2026$1.30B – $1.32BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Guardant Health filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. News
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. News
  9. News
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?